Mydecine Innovations Group announced the appointment of Josephine Wu, Founder and CIO at Aionious Management Ltd., to the company’s Board of Directors. Ms. Wu has over 18 years of hedge fund, family office and global asset management experience including 10 years of listed, pre-IPO and early-stage Pan-Asia healthcare investment experience. She has been CIO and portfolio manager with combined assets under management over US$5 billion. She is the founder and CIO of Aionious Management Limited. Additionally, Mydecine, with its appointment of Ms. Wu continues to focus on best practices in corporate governance. As a result, OTC markets has removed the Caveat Emptor designation, which had previously been associated with its stock ticker. The company continues to comply with all listing requirements of the OTC Markets and anticipates trading restrictions in the U.S. to be removed. Further, the company announces the resignation of Michael Connolly from the Board of Directors. The company would like to thank Mr. Connolly for his time, services and for the valuable contributions he made during his tenure as Director. Ms. Wu replaced Mr. Connolly on the Board of Directors.